Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06646497
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-13
Brief Title:
Indication of HSCT in Patients With RefractoryRelapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Evaluation of an Optimized Allogeneic Hematopoietic Stem Cell Transplantation Protocol With Post-transplant Cyclophosphamide in Patients Aged 40 to 60 Years Old With Acquired Aplastic Anemia Refractory or in Relapse After Immunosuppression
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
APARR
Brief Summary:
Outcomes for adult patients with Severe Aplastic Anemia SAA aged more than 40 years who are refractory or in relapse after first-line IST remain poor Hematopoietic stem cell transplantation HSCT is the unic valid therapeutic option but results have always been disappointing in patients aged 40 years or older The first cause of death after HSCT in those refractoryrelapse SAA patients is still graft versus host disease GvHD Recently new strategies to prevent GvHD including T-cell replete grafts with administration of post-transplantation cyclophosphamide PTCy have revolutionized the field notably in haplo-identical donor setting Using marrow as source of stem cells and a PTCy strategy not only in haplo-identical donor setting but also in case of an available matched sibling or unrelated donor might prevent drastically GvHD and eventually be practice changing Evaluating this new strategy is the main objectives of APARR
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None